Encompass Health Adds New Capacity With First Small-Format Hospital

Encompass Health plans a 24-bed small-format inpatient rehabilitation hospital in Conroe, Texas, for late 2027 and a 60-bed replacement hospital in The Woodlands for 2029, expanding its Houston-area capacity by 84 beds. The company expects to open eight hospitals totaling 389 beds in 2026 and add another 150-200 beds at existing facilities, supported by planned 2026 capital expenditures of $920 million-$995 million, including $695 million-$755 million for growth and replacement capacity. The investment will pressure near-term free cash flow and incur ramp-up costs but is intended to drive longer-term patient-volume and revenue growth.

Analysis

EHC's expansion is strategically constructive but not an earnings catalyst in the next 12 months: development spending and pre-opening losses arrive well before mature occupancy. The key valuation question is whether incremental facilities reach target census quickly enough to preserve returns on invested capital as construction, labor and financing costs remain elevated. A satellite model should improve fixed-cost absorption versus standalone builds, but it also concentrates referral and operational risk in the hub; this is a proof-of-concept to monitor rather than a basis for near-term multiple expansion.

The more investable second-order effect is regional capacity discipline. Incremental inpatient-rehab supply can pressure local discharge volumes and wage competition, but EHC's established referral relationships with acute-care systems create a meaningful barrier to smaller operators. THC is a potential indirect beneficiary where its Houston-area hospitals can improve discharge throughput through additional post-acute capacity; however, the effect is likely immaterial to consolidated earnings without a formal referral arrangement.

Consensus may underappreciate the cash-flow valley created by a multi-year build cycle. If bed ramp, reimbursement rates, or labor productivity disappoint, EHC could face an EBITDA-to-free-cash-flow conversion reset before the new assets contribute, particularly if management maintains growth capex. Conversely, sustained occupancy gains, stable therapy labor costs, and evidence that new sites mature on schedule would support a 6-18 month rerating as investors underwrite a larger revenue base. No material read-through exists for UNH or AVAH from this isolated capacity decision.

Key Decisions for Investors

• Maintain EHC as watchlist/market-weight rather than add on this announcement; reassess after the next two quarterly reports for same-store volume, labor-cost trends, and 2027 capex guidance. A meaningful upward revision to free-cash-flow conversion or demonstrated faster new-bed ramp would be the buy trigger.
• If EHC rallies materially ahead of fundamentals, consider a 3-6 month relative-value short EHC versus long THC: EHC carries execution and capex-ramp risk, while THC has nearer-term estimate momentum. Exit if EHC raises EBITDA guidance while holding growth capex flat or lower, or if THC's acute-care volumes weaken.
• Track Texas inpatient-rehab wage inflation and local occupancy data over the next 6-12 months. A sustained labor-cost acceleration or slower-than-planned census at recently opened EHC facilities would be a negative confirmation; no directional position is warranted until these data are available.
• Avoid using UNH or AVAH as direct proxies for this development. Their earnings sensitivity is dominated by payer utilization and home-health reimbursement dynamics, respectively, not a localized EHC capacity build.